Versant Vantage II GP, L.P. — SEC insider filings

SEC reporting owner CIK 1839790. 20 insider filings on record with FilingPulse; latest filed 2026-10-28.

Transaction summary — filings shown

Covers all 20 filings on record, filed 2021-06-23 to 2026-10-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
LENZ Therapeutics, Inc. (LENZ)10% owner101 leg · 180,000 sh · $3,060,00034 legs · 1,885,262 sh · $66,603,1395
Century Therapeutics, Inc. (IPSC)10% owner41 leg · 100,000 sh · $2,000,0001 leg · 550,000 sh · $7,166,6107
Turnstone Biologics Corp. (TSBX)10% owner24 legs · 225,000 sh · $2,700,000—27
Tempest Therapeutics, Inc. (TPST)10% owner2—2 legs · 787,999 sh · $967,033—
Lycia Therapeutics, Inc. (LYCA)10% owner2——4

Insider filings — Versant Vantage II GP, L.P.

FiledFormIssuerReported transactionsSource
2026-10-284Lycia Therapeutics, Inc. (LYCA)
jointly with Versant Ventures VII GP, L.P., Versant Venture Capital VII, L.P., Versant Ventures VII GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC
Conversion (C): 5,631,425 · Conversion (C): 1,393,882 · Conversion (C): 25,390,410 (derivative) · Conversion (C): 6,284,597 (derivative)EDGAR
2026-10-223Lycia Therapeutics, Inc. (LYCA)
jointly with Versant Ventures VII GP, L.P., Versant Venture Capital VII, L.P., Versant Ventures VII GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC
Holdings only — no transactions reportedEDGAR
2025-10-024LENZ Therapeutics, Inc. (LENZ)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC
Sale (S): 49,701 @ $45.35 · Sale (S): 34,405 @ $45.35 · Sale (S): 83,066 @ $46.41 · Sale (S): 57,502 @ $46.41 · Sale (S): 177 @ $47.01 · Sale (S): 123 @ $47.01EDGAR
2025-09-224LENZ Therapeutics, Inc. (LENZ)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC
Sale (S): 49,479 @ $41.59 · Sale (S): 24,370 @ $41.59 · Sale (S): 40,907 @ $43.00 · Sale (S): 20,148 @ $43.00 · Sale (S): 268 @ $43.30 · Sale (S): 132 @ $43.30EDGAR
2025-08-264LENZ Therapeutics, Inc. (LENZ)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC
Sale (S): 20,493 @ $40.03 · Sale (S): 10,076 @ $40.03 · Sale (S): 5,668 @ $40.59 · Sale (S): 2,809 @ $40.59 · Sale (S): 50,270 @ $39.53 · Sale (S): 24,760 @ $39.53 · +6 moreEDGAR
2025-08-194LENZ Therapeutics, Inc. (LENZ)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC
Sale (S): 145,051 @ $39.50 · Sale (S): 69,949 @ $39.50 · Sale (S): 30,628 @ $38.56 · Sale (S): 15,085 @ $38.56EDGAR
2025-08-124Turnstone Biologics Corp. (TSBX)
jointly with Versant Ventures V, LLC, Versant Venture Capital V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Affiliates Fund V, L.P., Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Capital V (Canada), LP, Versant Vantage II GP-GP, LLC, Versant Vantage II, L.P.
Code (U): 2,726,322 · Code (U): 207,486 · Code (U): 90,888 · Code (U): 82,006 · Code (U): 274,990EDGAR
2025-07-144LENZ Therapeutics, Inc. (LENZ)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC
Sale (S): 191,376 @ $34EDGAR
2025-07-014LENZ Therapeutics, Inc. (LENZ)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC
Sale (S): 200,000 @ $30.46EDGAR
2025-06-204LENZ Therapeutics, Inc. (LENZ)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC
Sale (S): 100,000 @ $29.95 · Sale (S): 100,877 @ $30.35 · Sale (S): 133,924 @ $30.25EDGAR
2025-06-124LENZ Therapeutics, Inc. (LENZ)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC
Sale (S): 350,000 @ $29EDGAR
2024-08-124Tempest Therapeutics, Inc. (TPST)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures IV, LLC, Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P.
Sale (S): 400,000 @ $1.35 · Sale (S): 387,999 @ $1.10EDGAR
2024-03-254LENZ Therapeutics, Inc. (LENZ)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC
Other (J): 598,203EDGAR
2023-07-274Turnstone Biologics Corp. (TSBX)
jointly with Versant Ventures V, LLC, Versant Venture Capital V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Affiliates Fund V, L.P., Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Capital V (Canada), LP, Versant Vantage II GP-GP, LLC, Versant Vantage II, L.P.
Conversion (C): 2,528,864 · Conversion (C): 192,458 · Conversion (C): 84,313 · Conversion (C): 76,067 · Conversion (C): 274,990 · Purchase (P): 197,458 @ $12 · +20 moreEDGAR
2022-08-114Century Therapeutics, Inc. (IPSC)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC
Sale (S): 550,000 @ $13.03 · Other (J): 364,800 @ $0EDGAR
2022-05-034Tempest Therapeutics, Inc. (TPST)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures IV, LLC, Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P.
Holdings only — no transactions reportedEDGAR
2022-02-024Century Therapeutics, Inc. (IPSC)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC
Other (J): 178,996 @ $0EDGAR
2021-12-284Century Therapeutics, Inc. (IPSC)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC
Other (J): 371,004 @ $0EDGAR
2021-07-014Graphite Bio, Inc. (GRPH)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC
Conversion (C): 12,343,727 · Conversion (C): 1,527,719 · Purchase (P): 180,000 @ $17 · Conversion (C): 30,019,945 (derivative) · Conversion (C): 3,715,415 (derivative)EDGAR
2021-06-234Century Therapeutics, Inc. (IPSC)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP-GP, LLC
Conversion (C): 9,936,011 · Conversion (C): 614,095 · Purchase (P): 100,000 @ $20 · Conversion (C): 25,000,000 (derivative) @ $0 · Conversion (C): 1,545,125 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-06-15 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1839790 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs